{
    "clinical_study": {
        "@rank": "8180", 
        "arm_group": {
            "arm_group_label": "AZD9150", 
            "arm_group_type": "Experimental", 
            "description": "There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B)."
        }, 
        "brief_summary": {
            "textblock": "This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability,\n      pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with\n      advanced/metastatic hepatocellular carcinoma."
        }, 
        "brief_title": "A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Adult Hepatocellular Carcinoma", 
            "Hepatocellular Carcinoma Metastatic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability,\n      Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with\n      Advanced/Metastatic Hepatocellular Carcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged at least 18 years. Patient from Japan and Taiwan aged at least 20 years\n\n          -  Histologically or cytologically confirmed HCC (with the exception of fibrolamellar\n             carcinoma or mixed variants of HCC with fibrolamellar histology OR clinically\n             diagnosed HCC for patients with difficulty in obtaining histological diagnosis)\n\n          -  Relapsed, refractory, intolerant or unlikely to benefit from sorafenib (for example\n             due to comorbidity)\n\n          -  Metastatic or locally advanced meeting ANY of the criteria below:\n\n          -  HCC not suitable to receive local therapy\n\n          -  Disease recurred or was refractory to last therapy (local or systemic)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no\n             deterioration over the previous 2 weeks and minimum life expectancy of 8 weeks\n\n        Exclusion Criteria:\n\n          -  More than 2 prior systemic treatments for HCC\n\n          -  Prior grade 3 hematologic toxicity related to treatment with a JAK or STAT3 inhibitor\n\n          -  Presence of hepatic encephalopathy within 4 weeks of 1st dose\n\n          -  Uncontrolled massive ascites\n\n          -  High likelihood of bleeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839604", 
            "org_study_id": "D5660C00001", 
            "secondary_id": "ISIS 481464"
        }, 
        "intervention": {
            "arm_group_label": "AZD9150", 
            "description": "Intravenous infusion over 3 hours.", 
            "intervention_name": "AZD9150", 
            "intervention_type": "Drug", 
            "other_name": "ISIS 481464"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Child-Pugh A to B7,", 
            "Advanced/Metastatic Hepatocellular Carcinoma,", 
            "AZD9150,", 
            "Antisense Oligonucleotide Inhibitor of STAT3"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hongkong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osakasayama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "Japan", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "800-236-9933"
        }, 
        "overall_official": {
            "affiliation": "AstraZeneca", 
            "last_name": "Frank Neumann, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "South Korea: Institutional Review Board", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Institutional Review Board", 
                "Taiwan: Institutional Review Board", 
                "Taiwan: Department of Health", 
                "Hong Kong: Department of Health", 
                "Hong Kong: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For routine safety monitoring, visit scheduled on Screening, Cycle1Day1, 3, 5, 8, 15 and 22, Day1, 8, 15 and 22 of every Cycle until study discontinuation and 28-day follow up,assessed up to 12 months.", 
            "measure": "Investigation of the safety and tolerability of AZD9150 when given intravenously to patients with hepatocellular carcinoma and determine a recommended phase II dose and schedule (RP2D) by evaluating dose limiting toxicities occurred during cycle 1.", 
            "safety_issue": "Yes", 
            "time_frame": "Assessed up to12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8, 15 and 22 of Cycle1 and Day1 of Cycle2-5. For additional 6 patients in Japan, 8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8 and 15 of Cycle1 and 9 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24, 72 hours post-dose) on Day22 Cycle1.", 
                "measure": "Evaluation of pharmacokinetics (PK) of AZD9150 (following a single and multiple administrations in patients with HCC by determining Cmax, using the plasma concentration data.", 
                "safety_issue": "No", 
                "time_frame": "8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8,15 and 22 of Cycle1 and on Day1 of Cycle2-5. Additional 6 patients in Japan; 8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8 and 15 of Cycle1 and 9 times on Day22 of Cycle1."
            }, 
            {
                "description": "Tumour response assessment by modified Response Evaluation Criteria in Solid Tumours (RECIST).", 
                "measure": "Obtaining of a preliminary assessment of the anti-tumour activity of AZD9150 by evaluation of tumour response.", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks, assessed up to 12 months."
            }, 
            {
                "description": "8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8, 15 and 22 of Cycle1 and Day1 of Cycle2-5 For additional 6 patients in Japan, 8 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24 hours post-dose) on Day1 of Cycle1, once (pre-dose) on Day 3, 5, 8 and 15 of Cycle1 and 9 times (pre-dose, 1.5, 3, 3.5, 4, 6, 8, 24, 72 hours post-dose) on Day22 Cycle1.", 
                "measure": "Evaluation of pharmacokinetics (PK) of AZD9150 (following a single and multiple administrations in patients with HCC by determining Tmax, using the plasma concentration data.", 
                "safety_issue": "No", 
                "time_frame": "8 times of PK sampling on Day1 of Cycle1 and once on Day3,5,8,15 and 22 of Cycle1 and on Day1 of Cycle2-5. Additional 6 patients in Japan; 8 times of PK sampling on Day 1 of Cycle 1 and once on Day3,5,8 and 15 of Cycle 1 and 9 times on Day 22 of cycle1."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}